NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee –– In four out of five ...
SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...
The company’s exhibitions will be focused in the areas of its pipeline, proprietary capsid engineering, and manufacturing. Thousand Oaks, Calif.-based Capsida Biotherapeutics (Capsida) has announced ...
Like scientific papers, oral presentations at a conference or internal seminar are for sharing your research work with other scientists. They, too, must convince the audience that the research ...
KT-621 demonstrated comparable or superior activity to dupilumab in reversing disease progression in a chronic asthma model, indicating its potential as an effective treatment option. Kymera ...
Informal Providers—Ground Realities in South Asian Association for Regional Cooperation Nations: Toward Better Cancer Primary Care: A Narrative Review Hidden oral cancer sites and residence in ...
In terms of safety, among participants receiving monotherapy and combination therapy, 19 (27.9%) and 26 (35.6%) reported treatment-related adverse events (TRAEs) of Grade 3 or higher, respectively.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback